Showing 1 posts of 1 posts found.
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia
Hot-tub therapy tested as potential treatment for peripheral artery disease
Raimond takes helm at Nuclera
Most advanced breast cancer patients treated in community settings, Phesi study finds
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison